"In conclusion, we confirm the efficacy of hydroxychloroquine associated with azithromycin in the treatment of COVID-19 and its potential effectiveness in the early impairment of contagiousness. Given the urgent therapeutic need to manage this disease with effective and safe drugs and given the negligible cost of both hydroxychloroquine and azithromycin, we believe that other teams should urgently evaluate this therapeutic strategy both to avoid the spread of the disease and to treat patients before severe irreversible respiratory complications take hold," the team concluded. 

Want to get on the nevbio list?  for information or rsvp to an event

​connect with nevbio today,  increase your opportunities tomorrow!

World of ​​blogs

News & noise

The Food and Drug Administration (FDA) has approved a molecular test that can diagnose novel coronavirus infections within a matter of minutes. The test, created by Abbott Laboratories, is highly portable and can be used in a wide variety of settings, from hospital emergency rooms to urgent care clinics to physicians' offices. The company says it expects to start shipping the kit out to health care providers next week, and that it will be able to deliver 50,000 tests a day by April 1

Google Translation: Hydroxychloroquine and Azithromycin is an effective treatment for # Covid_19fr, As you can see, the results are spectacular on D + 6 with a very significant drop in viral load. Bravo Pr #Raoult.

NevBio Blog
John Laub's bio & health science blog.

Biotechblog
Commercial, legal, political and scientific trends in biotechnology

Life Science Nation
Connecting Products, Services & Capital

Copyright 2013. NevBio: The Most Connected Biotechnology & Healthscience Organization in Nevada. 1120 N Town Center Suite 170, Las Vegas NV 89144

All rights reserved.

Las Vegas Based Company Approved to Conduct Parkinson's Trials


Las Vegas-based Zhittya Genesis Medicine, Inc. announced that it has received official regulatory approval from COFEPRIS, the Mexican governing body which would be the country's equivalent of the U.S. Food and Drug Administration (FDA), to test its novel biological drug in subjects with Parkinson's disease. The Phase I clinical study will be conducted at the Zambrano Hospital in Monterrey, Mexico, a new, state-of-the-art medical facility.

News IN Biotechnology & sciences

Dr. Didier Raoult, PhD, MD and his team had shown in a preliminary trial involving 36 COVID-19 patients that 100% of patients that received a combination of the two anti-malaria drugs tested negative and were virologically cured within 6 days of treatment. Link.
On Friday, March 27, Prof. Didier Raoult and his team published results of their new study. The study was supported by the Institut Hospitalo-Universitaire (IHU) Mediterranee Infection. The new observational study had a larger sample size of 80 COVID-19 patients. The objective of the study was to find an effective treatment to cure COVID-19 patients and to decrease the virus carriage duration.
The 80 patients received a combination of hydroxychloroquine and azithromycin. The team found clinical improvement in all but one 86 year-old patient who died, and one 74-year old patient who was still in the intensive care unit. The team also found that by administering hydroxychloroquine combined with azithromycin, they were able to observe an improvement in all cases, except in one patient who arrived with an advanced form, who was over the age of 86, and in whom the evolution was irreversible, according to a new paper published today in IHU Mediterranee Infection.

French Researchers Complete Additional Study on 80 Patients, Results Show a Combination of Hydroxychloroquine & Azithromycin to be Effective in Treating COVID-19
FDA Approves 5 Minutes Coronavirus Test